Training Example: GRAIL – Review the Data, Give Your Score & Compare to the Real AI Evaluation

[H2] OUR MISSION

[H1] Detect cancer early,when it can be cured.

About GRAIL

[H5] NEWS CENTER

[H5] PATIENT STORIES

[H5] SCIENTIFIC EVIDENCE

[H2] The Galleri® Test

[H3] A multi-cancer early detection (MCED) test

Capable of screening for cancers before they become symptomatic, including those that don’t have recommended screening tests today.
The Galleri test does not detect a signal for all cancers and not all cancers can be detected in the blood. False positive and false negative results do occur.

Learn more

[IMG: mced blood test vial]

[IMG: grail scientist]

[H2] Recent News

[H4]

GRAIL to Present at the Goldman Sachs 47th Annual Global Healthcare Conference

May 26, 2026

[H4]

GRAIL to Present at the 2026 Jefferies Global Healthcare Conference

May 21, 2026

[H4]

GRAIL Reports First Quarter 2026 Financial Results

May 5, 2026

[H2] “There's nothing in my family history that had me concerned for cancer...”

Kevin, a healthy firefighter of 30 years, took a multi-cancer early detection test offered by his fire department. Watch his inspring story.

Full story

[IMG: mced laboratory]

[H2] The Science Behind Multi-Cancer Early Detection

[H3] A new approach to screening for cancer

Multi-cancer early detection (MCED) represents a new frontier in cancer screening—using a simple blood test to identify signals from more than 50 types of cancer, including those without existing routine screening options.

Learn more

[IMG: cancer signal podcast logo]

[H3] The Cancer SIGNAL Podcast

On this podcast, we explore the stories behind multi-cancer early detection—from patients to doctors, researchers to advocates, and more.

Listen now

[IMG: email newsletter icon]

[H3] GRAIL Newsletter

Stay up to date on the latest news from GRAIL by signing up for our newsletter.

Sign up

[H1] Sign Up for Our Newsletter

[H1] News Center

See Media Resources

[H2] Featured Press Releases

[IMG: grail stock aug2025 113]

[H4]

GRAIL Reports First Quarter 2026 Financial Results

May 5, 2026

[IMG: grail stock aug2025 73 new]

[H4]

GRAIL to Present New Data From NHS-Galleri and PATHFINDER 2 at 2026 ASCO Annual Meeting

April 21, 2026

[IMG: dsc04260 scaled]

[H4]

GRAIL Announces Integration of the Galleri® Test into Epic Electronic Health Record Platform to Expand Access Nationwide

April 7, 2026

[IMG: grail stock aug2025 119]

[H4]

GRAIL Submits FDA Premarket Approval Application for the Galleri® Multi-Cancer Early Detection Test

January 29, 2026

Jump to:
PRESS RELEASES
GRAIL PERSPECTIVES
THE CANCER SIGNAL PODCAST

[H2] Press Releases

[H3]

GRAIL to Present at the Goldman Sachs 47th Annual Global Healthcare Conference

May 26, 2026

View Press Release

[H3]

GRAIL to Present at the 2026 Jefferies Global Healthcare Conference

May 21, 2026

View Press Release

[H3]

GRAIL Reports First Quarter 2026 Financial Results

May 5, 2026

View Press Release

[H3]

GRAIL to Present at the BofA Securities 2026 Health Care Conference

April 30, 2026

View Press Release

[H3]

GRAIL to Announce First Quarter 2026 Financial Results

April 22, 2026

View Press Release

[H3]

GRAIL to Present New Data From NHS-Galleri and PATHFINDER 2 at 2026 ASCO Annual Meeting

April 21, 2026

View Press Release

[H2] GRAIL Perspectives

[H3]

A Historic Moment in the Fight Against Cancer

February 3, 2026

Read More

[H3]

Why Finding Cancers Before It’s Too Late Matters More Than Ever

February 3, 2026

Read More

[H3]

The NHS-Galleri trial: What to expect in 2026 from the world’s first randomized controlled trial of a Multi-Cancer Early Detection test, Galleri®

November 6, 2025

Read More

[H3]

PATHFINDER 2: What to Expect from the Largest U.S. Multi-Cancer Early Detection (MCED) Interventional Trial

October 3, 2025

Read More

[H3]

Making Sense of the Numbers: Interpreting Multi-Cancer Early Detection Test Performance

September 30, 2025

Read More

[H3]

Not All MCED Tests are Created Equal: The Realities of MCED Test Development and Validation

July 31, 2025

Read More

[IMG: cancer signal podcast logo]

[H2] The Cancer SIGNAL Podcast

On this podcast, we explore the stories behind multi-cancer early detection—from patients to doctors, researchers to advocates, and more.

[IMG: apple podcasts]

[IMG: amazon music]

[IMG: spotify]

[IMG: overcast]

[H3] Host Rayshawnda Madison

Rayshawnda Madison is Head of Culture, Community, and Employee Experience at GRAIL, where she leads enterprise efforts focused on helping employees engage deeply in the company’s mission, feel a sense of belonging, and grow in ways that enable meaningful impact. Her work strengthens connection between people, purpose, and innovation in support of GRAIL’s goal to detect cancer early, when it can be cured.Working closely with leadership teams, Rayshawnda helps bring forward insight from employees and communities to better understand the experiences of the people GRAIL serves. She is particularly passionate about advancing health equity and supporting efforts that center patient experience and community perspective in how healthcare innovation reaches more people.

Read more

In addition to her role at GRAIL, Rayshawnda serves as Vice Chair of the Solano Commission for Women and Girls, where she helps advance initiatives focused on improving health outcomes for women and families, including birth justice efforts in her local community. She is a speaker and facilitator on topics related to culture, leadership, belonging, and health equity.As host of The Cancer SIGNAL, Rayshawnda brings curiosity, empathy, and a deep commitment to elevating the voices of patients, caregivers, clinicians, and innovators working to change the future of cancer detection.

[IMG: podcast host rayshawnda madison]

[H2] Episodes

[H3]

31 – When a Firefighter’s Cancer Is Detected Early

December 3, 2025

View Podcast

[H3]

30 – PATHFINDER 2 study results from ESMO 2025 with principal investigator Nima Nabavizadeh, MD

October 22, 2025

View Podcast

[H3]

29 – The Dallas Cowboys are Detecting Cancer Early

September 24, 2025

View Podcast

[H3]

28 – Jack’s Journey with Multi-Cancer Early Detection

June 6, 2025

View Podcast

[H3]

27 – Multi-Cancer Early Detection at the Doctor’s Office

March 20, 2025

View Podcast

[H3]

26 – The Role of Cancer Screening in Longevity

January 27, 2025

View Podcast

[H1] Our Story

[H2] Our mission is to detect cancer early, when it can be cured.

GRAIL is focused on alleviating the global burden of cancer by using the power of next-generation sequencing, population-scale clinical studies, and state-of-the-art machine learning, software, and automation to screen for many of the deadliest cancer types before symptoms appear.

[H1] Our History

Our story began in 2015, when an unexpected discovery unlocked a major breakthrough for changing lives at population scale.

See our history

[IMG: grail lab tour framecaps 64]

[IMG: grail stock aug2025 29]

[H2] The Galleri® test

Revolutionizing what’s possible in cancer screening with a first-of-its-kind, Multi-Cancer Early Detection (MCED) test.

Learn about the Galleri test

[H2] Backed by rigorous clinical evidence

>300 scientific publications and presentations>380K participants across unprecedented clinical program

View our clinical studies

[IMG: grail stock aug2025 58]

[IMG: grail locations (1)]

[H2] Locations

>170,000 square feet of CAP-accredited, CLIA-certified lab facilities with sufficient capacity to support multiple years of growth.

[H2] Leadership

Our leadership team is driven by a common purpose—to advance technology that can help detect cancer early.

Meet our leaders

[IMG: grail stock aug2025 27 1]

[IMG: grail lab tour framecaps 121]

[H2] Join our team​

Our talented employee pool includes expertise from individuals with a variety of backgrounds and specialties, enriching our collective knowledge and skill-base.

Working at GRAIL

[H2] Awards

2025 Best Place to Work Lists Built In & BioSpace2023 Change the World List, Fortune2022 World Changing Ideas Awards, Fast CompanyBreakthroughs of the Year List, 2022, The AtlanticIntelligent Diagnostics Silver Winner, 2023, The Edison AwardsBest Inventions of 2022 List, Time Magazine

[H2] Explore more

Contact us

View press releases

Listen to The Cancer SIGNAL Podcast

Sign up for our newsletter

[IMG: grail stock aug2025 48]

[H1] Our History

[H2] An unexpected discovery unlocks a major breakthrough for changing lives at population scale

[H3] An Unexpected Discovery

[H3] 2015-2017

[H3] We didn’t start off looking for a way to detect cancer.

In 2015, Illumina’s non-invasive prenatal test (NIPT) unexpectedly detected genomic abnormalities in pregnant mothers that were unrelated to the health of their children. The test detected cell-free DNA from cancer present in the mother’s blood.
In 2016, Illumina spun out a separate entity to focus on researching this incredible discovery, naming it GRAIL because the co-founders believed a simple blood test could be the “holy GRAIL” of cancer detection. With a focus on scientific excellence, transparency, and a vision for what was possible, we raised the funds required to pursue this revolutionary idea.

2015:

2016:

2017:

[H2] 2015:

July: Journal of the American Medical Association (JAMA) publishes discovery of cancer signals found in the blood of asymptomatic women

[H2] 2016:

January: GRAIL is foundedDecember: GRAIL announces Circulating Cell-free Genome Atlas (CCGA) study as foundation for development of blood test to detect cancer early

[H2] 2017:

March: $1B Series B funding announced after initial $100M Series A. GRAIL acquires Cirina and key methylation IPApril: GRAIL initiates the STRIVE study to advance development of blood tests to detect cancer early

[H2] A Major Breakthrough

[H3] 2018-2019

[H3] We saw new possibilities, and dared ourselves to pursue a bold vision.

How can one breakthrough unlock others? Through research and early clinical data, we learned to pivot our focus from screening for individual cancers to screening for multiple cancers, pioneering the multi-cancer early detection (MCED) category.This inspired an even greater sense of urgency to build the foundation for gathering and sharing clinical study data. To pursue our mission of detecting cancer early, when it can be cured, we scaled our operations, expanded to the UK, and assembled the team that would elevate GRAIL to the next level.

2018:

2019:

[H2] 2018:

July: At the American Association for Cancer Research (AACR) GRAIL presents data supporting multi-cancer early detectionDecember: GRAIL announces plans to initiate SUMMIT study to support development of blood test for early cancer detection

[H2] 2019:

May: GRAIL earns Breakthrough Device Designation from FDA for MCED test
May: $300M in Series C funding announced.
May, June, October: Circulating Cell-free Genome Atlas (CCGA) Study data presented to the scientific community.

[H2] Life Changing Advances

[H3] 2020-2021

[H3] We saw how our work could change the cancer continuum.

We expanded our clinical capabilities by building a presence in Research Triangle Park (RTP), NC. We announced a partnership with the UK government to broaden our global impact.We announced collaborations with leading pharmaceutical companies and began testing Post-Diagnosis (PDx) and Diagnostic Aid for Cancer (DAC) models. We celebrated the commercial launch of Galleri®, the first-of-its-kind multi-cancer early detection test.

2020:

2021:

[H2] 2020:

February: PATHFINDER study begins enrolling to evaluate MCED test in clinical practiceMarch: The Annals of Oncology publishes validation data showing an MCED test detects a signal shared by 50+ cancersMay: $390M in Series D funding announcedNovember: GRAIL partners with UK’s National Health ServiceDecember: A manuscript published in Cancer Epidemiology, Biomarkers & Prevention models the MCED test showing a reduction in late-stage diagnoses by more than half

[H2] 2021:

March: GRAIL announces Providence as first healthcare system to offer GalleriJune: the Galleri test is launched, available by prescription in the USAugust: Illumina’s acquisition of GRAIL announcedSeptember: NHS launches UK trial of the Galleri test

[H2] Population-Scale Impact

[H3] 2022-2023

As we scaled, we kept patients as our top priority. We shifted our focus to the audacious goal of redefining the status quo of cancer detection, which requires broad-scale engagement with the healthcare ecosystem—from patients and providers to partners and payers.We pursued partnerships to improve cancer detection rates for underserved populations and those at higher risk for cancer, such as veterans. We navigated political and regulatory landscapes, and made progress in our mission by attracting talent, partners, and customers committed to creating a better tomorrow.

[IMG: grail stock aug2025 65 new]

2022:

2023:

[H2] 2022:

May: GRAIL announces collaboration with U.S. Department of Veterans Affairs and the Veterans Health Foundation to evaluate the Galleri test.June: GRAIL announces strategic collaboration with AstraZeneca to develop companion diagnostic tests to enable the treatment of early-stage cancer.July: GRAIL and National Health Service (NHS) England complete enrollment of 140,000 participants in largest study of multi-cancer early detection test in just over ten months.September: GRAIL announces final results from the PATHFINDER Multi-Cancer Early Detection Screening Study at ESMO Congress 2022.September: John Hancock becomes first life insurance carrier to offer access to GRAIL’s multi-cancer early detection test to customers.November: CCGA discovery results published in Cancer Cell reveal methylation as promising DNA hallmark for multi-cancer early detection.

[H2] 2023:

January: GRAIL introduces state-of-the-art methylation-based solution to accelerate cancer research in the post-diagnosis settingJune: SYMPLIFY results presented at the American Society of Clinical Oncology Conference, showing promise as Diagnostic Aid for Cancer.June: The Lancet Oncology publishes results from SYMPLIFY, the first prospective study of a multi-cancer early detection test in a symptomatic patient populationJune: GRAIL announces 100,000 commercial Galleri test reports delivered to patientsAugust: Whitman-Walker Institute, Cancer Support Community and GRAIL collaborate on research aimed at advancing health equity in cancer screening and care through multi-cancer early detectionOctober: Final results from PATHFINDER study of GRAIL’s multi-cancer early detection blood test published in The Lancet.November: GRAIL to initiate REACH study to evaluate clinical impact of Galleri® multi-cancer early detection test among the Medicare population

[H2] Continued Momentum

[H3] 2024-2025

[H3] We are building what’s next in cancer detection.

We have worked to expand access and deepen clinical research as we embark on our next chapter as an independent, publicly traded company. As part of our commitment to innovation, we added new platform integrations, advanced strategic partnerships, presented meaningful results from clinical studies, and built the operational foundation to scale.

2024:

2025:

[H2] 2024:

January: BeniComp adds GRAIL’s multi-cancer early detection test as part of employee health screening benefitsFebruary: Curative Insurance Company adds the Galleri® test to health plan benefits with no out-of-pocket cost for members*March: GRAIL announces a novel risk classification test to be used in lung cancer study in collaboration with AstraZenecaMarch: GRAIL presents new findings on repeat screening with the Galleri® test and its methylation platform at the American Association for Cancer Research (AACR) Annual MeetingJune: Illumina Board of Directors approves spin-off of GRAIL; company begins trading on Nasdaq under the symbol “GRAL”July: First participant enrolled in the REACH study evaluating the clinical impact of the Galleri® test in diverse and underrepresented groups in the Medicare populationAugust: JCO Precision Oncology publishes new data on the Galleri® test performance in individuals with prostate cancerOctober: Initial results from the REFLECTION study presented at the Early Detection of Cancer Conference (EDCC); participants include veterans with toxic exposureNovember: GRAIL reports commercial delivery of more than 250,000 Galleri® tests since launch

[H2] 2025:

January: The Lancet Oncology publishes PATHFINDER patient-reported outcomes showing minimal distress associated with multi-cancer early detection testingFebruary: The Galleri® test becomes available through the Quest Diagnostics ordering platform, helping streamline the provider patient experienceApril: GRAIL presents new data on the Galleri test and its methylation platform at the AACR Annual Meeting; real-world evidence includes results from more than 100,000 patientsMay: GRAIL and athenahealth announce collaboration to enable provider ordering of the Galleri testMay: GRAIL announces top-line results from the prevalent screening round of the NHS-Galleri trial, showing a substantially higher positive predictive value (PPV) than that observed in the PATHFINDER study.September: Samsung and GRAIL announce strategic collaboration to bring Galleri test to AsiaOctober: GRAIL presents results from PATHFINDER 2 study at the European Society for Medical Oncology (ESMO) Congress 2025, showing the Galleri test increased cancer detection more than seven-fold when added to USPSTF A and B recommended screeningsOctober: GRAIL and University of Oxford present long-term data from the SYMPLIFY study evaluating the Galleri test in symptomatic individuals at the Early Detection of Cancer Conference (EDCC)October: GRAIL announces $325.0 million private placement financing

[H2] What’s next?

As we look to the future, we’re focused on reaching more patients around the globe, advancing critical research, and expanding partnerships to help reach our vision of population-scale multi-cancer early detection.

[H2] Important Safety Information

The Galleri test is recommended for use in adults with an elevated risk for cancer, such as those age 50 or older. The test does not detect all cancers and should be used in addition to routine cancer screening tests recommended by a healthcare provider. The Galleri test is intended to detect cancer signals and predict where in the body the cancer signal is located. Use of the test is not recommended in individuals who are pregnant, 21 years old or younger, or undergoing active cancer treatment. Results should be interpreted by a healthcare provider in the context of medical history, clinical signs and symptoms. A test result of No Cancer Signal Detected does not rule out cancer. A test result of Cancer Signal Detected requires confirmatory diagnostic evaluation by medically established procedures (e.g. imaging) to confirm cancer. If cancer is not confirmed with further testing, it could mean that cancer is not present or testing was insufficient to detect cancer, including due to the cancer being located in a different part of the body. False positive (a cancer signal detected when cancer is not present) and false negative (a cancer signal not detected when cancer is present) test results do occur. Rx only.

[H2] Laboratory/test information

The GRAIL clinical laboratory is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) and accredited by the College of American Pathologists. The Galleri test was developed—and its performance characteristics were determined—by GRAIL. The Galleri test has not been cleared or approved by the Food and Drug Administration. The GRAIL clinical laboratory is regulated under CLIA to perform high-complexity testing. The Galleri test is intended for clinical purposes.